the ALTA 1L Trial

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

Retrieved on: 
Friday, May 22, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Brain metastasis, Brain tumor, Lung cancer, the ALTA 1L Trial, ALUNBRIG® (brigatinib), ALK+ NSCLC, Takeda Pharmaceutical Company Limited

We believe this approval for ALUNBRIG is a substantial step in the right direction and represents significant progress for Takedas broader lung cancer portfolio.

Key Points: 
  • We believe this approval for ALUNBRIG is a substantial step in the right direction and represents significant progress for Takedas broader lung cancer portfolio.
  • Twenty-nine percent of patients had brain metastases at baseline in the ALUNBRIG arm versus 30% in the crizotinib arm.
  • In the ALTA 1L trial, serious adverse reactions occurred in 33% of patients receiving ALUNBRIG.
  • In the ALUNBRIG arm of trial ALTA 1L (180 mg once daily), ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG.